Recursion announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion?s research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion?s Board of Directors.

Dr. Khan has deep expertise in the pharmaceutical and healthcare industry, spanning biological, chemical, and medical science, computational and data science, and general business leadership, with a focus on driving substantial patient and business value. As the Chief Data Science Officer and Global Head of Strategy and Portfolio Organization, for Innovative Medicine R&D at Johnson & Johnson, Najat played an integral role with the senior leadership team in building an industry-leading pipeline that delivered multiple transformational medicines. She has been a pioneer in driving the impact of data science/AI at scale while establishing a top-tier diverse data science team, underpinning her commitment to innovation and excellence at the intersection of healthcare and technology.

Dr. Khan co-chaired Johnson & Johnson?s Data Science Council, where she has played a key leadership role in driving the adoption of data science across the company to achieve business impact and deploy best practices for data use, AI, ethics, as well talent recruitment and development. Dr. Khan serves as a board member for Alliance for Artificial Intelligence in Healthcare and is a Steering Committee member of the White House?s Moonshot CancerX program to enhance outcomes for cancer patients. Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) ?

a cross industry forum dedicated to driving impact through Data Science. She is an alumna of University of Pennsylvania with a doctorate in Organic Chemistry leveraging experimental and computational approaches, has an undergraduate degree in Computational Chemistry and a minor in Business /Economics from Colgate University, and is published in various high-impact journals.